The Journal of Practical Medicine >
Analysis of early predictors of severe and critical SARS⁃CoV⁃2 infection
Received date: 2023-07-15
Online published: 2023-12-19
Objective To explore the early predictors of the development of the novel coronavirus infection (COVID-19) into severe and critical forms. Methods COVID-19 patients hospitalized in the Department of Intensive Care Medicine, Infection ward, Respiratory and Critical Care Medicine of the First Affiliated Hospital of Guangxi Medical University from December 2022 to March 2023 were selected as the study objects, and were divided into mild/medium group, severe group, and critical group according to the severity of illness during hospitalization. General clinical data and early laboratory results of the three groups were collected and compared. Results A total of 242 patients with novel coronavirus infection were included, including 117 mild/medium patients, 55 severe patients, and 70 critically severe patients. There were 165 males and 77 females with a median age of 70 (59,80) years. The age, sex, diabetes, heart disease, stroke, combined pneumonia, combined bloodstream infection, APACHE Ⅱ score, respiratory rate on admission, systolic blood pressure, and early white blood cell count (WBC), lymphocyte count (LYM), urea, creatinine, albumin, C-reactive protein, D-dimer, interleukin-6 (IL-6), and calcium reduction of patients in the three groups had significant (all P < 0.05). Ordered logistic regression shows, previous heart disease, stroke, combined bloodstream infection, WBC, high IL-6 level, and low LYM level were independent risk factors for severe and critical COVID-19 infection [odds ratio (OR) and 95% confidence interval (95%CI) were 3.253(1.694 ~ 6.246), 5.251(2.378 ~ 11.592), respectively. 6.920(2.499 ~ 19.189), 1.111(1.041 ~ 1.186), 1.003(1.001 ~ 1.006), 0.571(0.353 ~ 0.926)]. ROC curve analysis showed that WBC, LYM, IL-6 and their combined detection had certain predictive value for the severity of COVID-19 (all P < 0.05), and the combined detection of WBC, LYM and IL-6 had better predictive value than a single indicator (P < 0.05). Conclusion Previous heart disease, cerebrovascular disease, early combination of bloodstream infection, high levels of IL-6, white blood cell count, and low lymphocyte levels at admission were independent risk factors that helped to predict the severity of COVID-19 infection early. The combined detection of WBC, LYM and IL-6 has certain predictive value for the development of severe and critical COVID-19.
Key words: coronavirus disease 2019; severity; risk factors
Bin HUANG , Fengkun LU , Xiaorong LI , Zhanhong TANG , Juntao Hu . Analysis of early predictors of severe and critical SARS⁃CoV⁃2 infection[J]. The Journal of Practical Medicine, 2023 , 39(21) : 2736 -2742 . DOI: 10.3969/j.issn.1006-5725.2023.21.008
| 1 | GALLO MARIN B, AGHAGOLI G, LAVINE K, et al. Predictors of COVID-19 severity: A literature review [J]. Rev Med Virol, 2021, 31(1): 1-10. |
| 2 | FRICKE-GALINDO I, FALFáN-VALENCIA R. Genetics Insight for COVID-19 Susceptibility and Severity: A Review [J]. Front Immunol, 2021, 12: 622176. |
| 3 | 中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版) [J]. 中国合理用药探索, 2023, 20(1): 1-11. |
| 4 | MATTIUZZI C, LIPPI G. Which lessons shall we learn from the 2019 novel coronavirus outbreak? [J]. Ann Transl Med, 2020, 8(3): 48. |
| 5 | BLACKBURN R, ZHAO H, PEBODY R, et al. Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004-2015 [J]. Clin Infect Dis, 2018, 67(1): 8-17. |
| 6 | CORRALES-MEDINA V F, MUSHER D M, SHACHKINA S, et al. Acute pneumonia and the cardiovascular system [J]. Lancet, 2013, 381(9865): 496-505. |
| 7 | LI B, YANG J, ZHAO F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China [J]. Clin Res Cardiol, 2020, 109(5): 531-538. |
| 8 | VOSKO I, ZIRLIK A, BUGGER H. Impact of COVID-19 on Cardiovascular Disease [J]. Viruses, 2023, 15(2):508. |
| 9 | BOURGONJE A R, ABDULLE A E, TIMENS W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) [J]. J Pathol, 2020, 251(3): 228-248. |
| 10 | SONG J, LI Y, HUANG X, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2 [J]. J Med Virol, 2020, 92(11): 2556-2566. |
| 11 | SOUSA RêGO L O, ALVES BRAGA L L, VILAS-BOAS G S, et al. Cardiovascular and Neurological Complications of COVID-19: A Narrative Review [J]. J Clin Med, 2023, 12(8):2819. |
| 12 | CHANG W T, TOH H S, LIAO C T, et al. Cardiac Involvement of COVID-19: A Comprehensive Review [J]. Am J Med Sci, 2021, 361(1): 14-22. |
| 13 | GLUCKMAN T J, BHAVE N M, ALLEN L A, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee [J]. J Am Coll Cardiol, 2022, 79(17): 1717-1756. |
| 14 | MAUER N, CHIECCA G, CARIOLI G, et al. The First 110,593 COVID-19 Patients Hospitalised in Lombardy: A Regionwide Analysis of Case Characteristics, Risk Factors and Clinical Outcomes [J]. Int J Public Health, 2022, 67: 1604427. |
| 15 | BONNET G, WEIZMAN O, TRIMAILLE A, et al. Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study [J]. Arch Cardiovasc Dis, 2021, 114(5): 352-363. |
| 16 | CHEN J, LIU Y, QIN J, et al. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study [J]. Postgrad Med J, 2022, 98(1161): 515-522. |
| 17 | SUN Y, GUAN X, JIA L, et al. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and GuangguFangcang Shelter Hospital [J]. J Clin Hypertens (Greenwich), 2021, 23(2): 218-231. |
| 18 | D'ELIA L, GIAQUINTO A, ZARRELLA A F, et al. Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of observational studies after 2 years of pandemic [J]. Eur J Intern Med, 2023, 108: 28-36. |
| 19 | WANG M, ZHANG H, HE Y, et al. Association Between Ischemic Stroke and COVID-19 in China: A Population-Based Retrospective Study [J]. Front Med (Lausanne), 2021, 8: 792487. |
| 20 | BALCOM E F, NATH A, POWER C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease [J]. Brain, 2021, 144(12): 3576-3588. |
| 21 | STAMM B, HUANG D, ROYAN R, et al. Pathomechanisms and Treatment Implications for Stroke in COVID-19: A Review of the Literature [J]. Life (Basel), 2022, 12(2):207. |
| 22 | LIU X, ZHANG R, HE G. Hematological findings in coronavirus disease 2019: indications of progression of disease [J]. Ann Hematol, 2020, 99(7): 1421-1428. |
| 23 | CHEN T, WU D, CHEN H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [J]. BMJ, 2020, 368: m1091. |
| 24 | DENG Z, ZHANG M, ZHU T, et al. Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19 [J]. Int J Infect Dis, 2020, 98: 353-358. |
| 25 | AN A Y, BAGHELA A, ZHANG P, et al. Severe COVID-19 and non-COVID-19 severe sepsis converge transcriptionally after a week in the intensive care unit, indicating common disease mechanisms [J]. Front Immunol, 2023, 14: 1167917. |
| 26 | QUDUS M S, TIAN M, SIRAJUDDIN S, et al. The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection [J]. J Med Virol, 2023, 95(4): e28751. |
| 27 | KNOLL R, SCHULTZE J L, SCHULTE-SCHREPPING J. Monocytes and Macrophages in COVID-19 [J]. Front Immunol, 2021, 12: 720109. |
| 28 | YIU H H, GRAHAM A L, STENGEL R F. Dynamics of a cytokine storm [J]. PLoS One, 2012, 7(10): e45027. |
| 29 | 唐劲松,宣春,林景涛,等.C-反应蛋白、白介素-6及降钙素原检测在新冠肺炎中的临床意义[J].实用医学杂志,2020,36(7):839-841. |
| 30 | FUJINO M, ISHII M, TANIGUCHI T, et al. The Value of Interleukin-6 among Several Inflammatory Markers as a Predictor of Respiratory Failure in COVID-19 Patients [J]. Diagnostics (Basel), 2021, 11(8):1327. |
| 31 | HEROLD T, JURINOVIC V, ARNREICH C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 [J]. J Allergy Clin Immunol, 2020, 146(1): 128-136.e4. |
| 32 | AZIZ M, FATIMA R, ASSALY R. Elevated interleukin-6 and severe COVID-19: A meta-analysis [J]. J Med Virol, 2020, 92(11): 2283-2285. |
| 33 | YANG C, ZHAO H. Tocilizumab in COVID-19 therapy: who benefits, and how? [J]. Lancet, 2021, 398(10297): 299. |
| 34 | WU J, SHEN J, HAN Y, et al. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment [J]. Front Immunol, 2021, 12: 598799. |
/
| 〈 |
|
〉 |